The FDA has authorized a new version of the Novavax vaccine targeting the JN1 strain, which has become the dominant seasonal variant. Health officials compare the current state of COVID-19 to the common cold, noting that the virus continues to mutate but at a more stable rate than the flu. Additionally, a new Moderna vaccine named "M Nex Spike" has received approval as the pharmaceutical industry continues its booster strategy.
